Sarepta Therapeutics (SRPT) Misses Q1 EPS by 24c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments
April 27, 2017 4:01 PM EDT-- First quarter 2017 EXONDYS 51 total net revenues of $16.3 million --
-- Company anticipates net revenues for the year will exceed $95 million --
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today reported financial results for the first quarter of 2017.
The first quarter of 2017 showed significant progress across all areas of the business, including executing a strong launch for EXONDYS 51 (eteplirsen),... More
